Register for free to
view the full innovation profile.
First-in-class; tracking of COPD disease severity; non-invasive
About
Chronic Obstructive Pulmonary Disease (COPD) is presented by the obstruction in airflow to and from the lungs. It is a complex disease, whose progression is difficult to predict. To date, no biomarker is capable of indicating disease severity for COPD. We have filed a patent for a new COPD assay which allows for the classification of disease progression in COPD. The assay uses a patient’s immune reaction to measure levels of modified protein. This is a non-invasive test that could be used in personalising healthcare and can be used in both trial and clinical settings. This novel COPD assay is now available for co-development or licensing. When contacting us, please quote our internal reference number 6445.